ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO's approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics.

<p>ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO&#39;s approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics. ARTBIO is working with SpectronRx to develop a new prostate cancer therapy called AB001.</p>


ARTBIO

Clinical and Preclinical Quality Director

Senior Director, Clinical Operations

Senior Director, Intellectual Property

Director of Clinical Data Management

Senior Medical Director, Clinical Development


              ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
            

SpectronRx, ARTBIO Partner On Alpha Radioligand Therapy - Contract Pharma

ARTBIO, Nucleus RadioPharma Enter Manufacturing & Supply Pact - Contract Pharma

 Artbio brings in $90M for radioactive molecules that target cancer 

Artbio emerges with $23M to make radioligand therapies for prostate cancer, with field still in 'early days' - Endpoints News

ARTBIO, Nucleus RadioPharma Partner to Advance Targeted Alpha Radioligand Therapies for Cancer - HIT Consultant

 ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer 

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential - PR Newswire

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors - BioWorld Online


                New NIST Standard Helps Deliver the Right Dosage of Cancer-Fighting Drugs
              

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials - Business Wire

ARTBIO, PharmaLogic Enter Manufacturing and Supply Pact - Contract Pharma

Thor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228 - NTB Kommunikasjon

Thor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228ARTBIO, Thor Medical | October 29, 2024

Swiss Biotech Day is here! ARTBIO is participating and supporting the Swiss biotech ecosystem with two important contributions by our CEO Emanuele Ostuni:
 
Unleashing the power of Alpha Radioligand Therapy (ART) tomorrow at 12:45
 
Radio Therapy Panel sponsored by Molecular Partners tomorrow at 15.00 - hosted by Philippe Legenne, with  Melpomeni Fani, University Hospital Basel, Sibylle Jennings, Novartis and Arnaud Lesegretain, Orano Med. 

We look forward to the insights and continued progress for the field of #alpha #radioligand #therapy

#nuclearmedicine #radiopharmaceuticals #swissbiotechday

Ivana Galetic Conrad Wüller Swiss Biotech Association

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer - Chemical & Engineering News

 ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors 

J&J’s Margaret Yu named Artbio CMO - The Pharma Letter

ARTBIO, PharmaLogic Enter Manufacturing And Supply Pact - Contract Pharma

Our very own Victor Paulus was featured in the latest episode of “A Dose of Reality” podcast. It’s talented and driven colleagues like Victor that help build ARTBIO and enable us to bring life-changing and innovative #alpha #radioligand #therapies to patients in need.
 
Check out the episode in the link below to learn why ARTBIO is a special place for Victor, but also to learn from his experiences in regulatory, drug development the exciting space of #radiopharmaceuticals.


              Emanuele Ostuni - CEO, ARTBIO
            

ARTBIO Announces Appointment of Nicole Hadas as Chief Legal OfficerARTBIO | January 21, 2025

Technical Operations & ManufacturingRadioprotection OfficerOslo

Thor Medical and ARTBIO Forge Strategic Supply Partnership - TipRanks

Please join us in welcoming Amra Demirovic as Chief Human Resources Officer!

Amra brings extensive experience in human resources and a proven track record of fostering inclusive workplace cultures. Amra comes to us from BeiGene, where she led HR for Europe & New Markets. Prior to that, she held key HR positions at Novartis. 

Amra loves sports and exploring the world with her son.

Welcome to the team, Amra! 

#nuclearmedicine #radioligandtherapy #radiopharmaceuticals #biotech #team

 SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy ... 

☢️ New job alert!

ARTBIO is looking for a Clinical Trial Finance Associate. This role will support the Clinical Operations team and can be in London or Boston. It's a great opportunity to support a biotech that is innovating alpha radioligand therapies for patient-centric cancer care!

Apply here or reach out to me directly. 

#hiring #financeassociate #clinicaloperations #hiringinbiotech #clinicaltrialbudgeting #newjob #RLT



                Breakthrough mini-protein revolutionizes how we treat cancer
              


                Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer - European Journal of Nuclear Medicine and Molecular Imaging
              

Redefining cancer care is not only about taking the right medication. Early cancer detection is a vital tool in the battle against prostate cancer. That’s why we are proud to support Prostate Cancer Research’s latest #ProactiveForYourProstate campaign. 
 
In the UK and elsewhere, prostate cancer is now one of the most common cancer types. We applaud PCR’s efforts to establish a national screening program in the UK designed to detect prostate cancer early when it’s the most treatable.
 
ARTBIO is proud to be a Proactive Champion supporter. If you’re interested in helping to advance this worthwhile cause, please consider joining PRC’s Campaign Action Network: https://lnkd.in/ezkJSSgk 
 
#prostatecancer #oncology #preventativemedicine #biotech #nuclearmedicine

FogPharma, ARTBIO Partner to Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma

ARTBIO has a new home for bold ideas and breakthrough science. We have relocated our European research labs to Forskningsparken - Oslo Science Park, opening the door to expanded research #collaborations, new academic #partnerships, and advancing cutting-edge, radiation-enabled R&D and #technology development.
 
 
This move marks more than a change in address. We’re building a space designed to inspire scientific excellence in radiopharmaceutical, preclinical biology research and generate technology advancements for novel cancer treatments. Our new lab brings us even closer to leading academic institutions, research partners, and hospital systems, enabling deeper collaboration and faster progress for the patients we serve.

To our new partners, colleagues, and #community: Thank you for being part of this journey. We can’t wait to get started. Read the press release here: https://lnkd.in/dpagWf4e 
 
#nuclearmedicine #biotech #radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare

Cody AS Thor Medical ASA Jasper C. Kurth Oncoinvent ASA Oslo Cancer Cluster Bjørn Erik Reinseth RADFORSK Anders Tuv Ole Kristian Hjelstuen Leif Rune Skymoen The Life Science Cluster Hanne Mette Kristensen Magnus Skoglund Larsen Hans-Peter Daae

ARTBIO Expands Radiopharmaceutical R&D Capabilities with Move to Oslo Science ParkARTBIO, Oslo Science Park | May 16, 2025


              New England Venture Capital Association Announces Nominees for the 12th Annual NEVY Awards
            

 Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities 

ARTBIO divulges plans for proprietary isotope manufacturing technology - Pharmaceutical Technology

Deals Report: J&J acquires Proteologix, Fog-ARTbio to develop radiotherapies - BioCentury

Thor Medical invitation to capital markets update | Thor Medical ASA - NTB Kommunikasjon

 “Survivor 45” exclusive deleted scene flashes back to day 1 of ... 

🏃♀️ 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗺𝗼𝘁𝗶𝗼𝗻! 🏃♂️

This past Saturday, NucliThera laced up for 𝗛𝗼𝗹𝗺𝗲𝗻𝗸𝗼𝗹𝗹𝘀𝘁𝗮𝗳𝗲𝘁𝘁𝗲𝗻 - one of the world's largest relay races - joining forces with our colleagues from ARTBIO and Oncoinvent ASA to form a 𝘂𝗻𝗶𝘁𝗲𝗱 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗿𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗲𝗮𝗺!

As a small and growing company, collaboration is at the heart of what we do — not just in science, but in spirit. We're proud that Anna Maria Sæther represented NucliThera on the course, embodying the energy and determination we bring to our mission: delivering new and effective treatments to people living with cancer.

This year also celebrates 50 years of female participation in the event — a powerful reminder of the progress that can be made when barriers are broken and inclusion is prioritized.

👏 Huge thanks to everyone who ran, cheered, and made it a day to remember. It was a celebration of science, health, and shared determination — on the track and beyond 💪

🎉 Special thanks to Elisa Napoli, PhD, whose initiative and organization turned this idea into an unforgettable race-day collaboration.

#Holmenkollstafetten #RadioligandTherapy #NucliThera #CancerResearch #WomenInScience #Collaboration

Tanja Aarvak, Elise Damlien, Roxanne Wouters, Kim Lindland, Amaury Guillou, PhD, Nisarg Soni, Ph.D, Wouter van Eijmeren, Ruth Gong Li, Richard Crispin, Célia Seillier, PhD

Fogpharma and Artbio collaborate to create new class of α-radioligand therapeutics for solid tumors - BioWorld MedTech

ARTBIO and Oslo University Hospital Announce Collaboration to Advance the Research and Development of Alpha Radioligand TherapiesARTBIO, Oslo University Hospital | June 5, 2024

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities - Business Wire

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline - The Pharma Letter

Artbio brings in $90M for radioactive molecules that target cancer - The Business Journals

 GSK, Novartis, among winners at LSX Awards - BioProcess ... 

At ARTBIO, we are full of pride. Not only because of our patient-centric programs, but because we value our #employees and #partners who contribute diverse viewpoints and opinions. Before this #Pride #Month comes to a close, ARTBIO celebrates all individuals who bring their authentic self to work each and every day. ARTBIO will always be a place to call home regardless of your lifestyle. If you’re interested in learning more about our company culture and exploring current opportunities, visit www.artbio.com. 

#radiopharmaceuticals #nuclearmedicine #alpha #radioligand #therapy

The European Association of Nuclear Medicine (EANM) Annual Congress kicks off this Saturday and we’re thrilled to be attending! 

Join us as we explore the latest advancements in #NuclearMedicine, share insights with industry leaders, and connect with fellow innovators. Together, we can shape the future of patient care and drive meaningful change in the field. Stay tuned for updates from the event!

#EANM24 #RadioligandTherapy #Radiopharmaceuticals #Biotech

Emanuele Ostuni | Conrad Wüller | ✪ Philippe Dasse ✪ ☤ | Daniel Rossetto | Phil Ruis | Vicki Jardine | Ivana Galetic | Mohana Suppiah-Coll | Tanja Aarvak | Elisa Fiorito, Ph.D. | Vilde Yuli Stenberg | Joshua Needham-Clark | Rosa Greasley | Jordi Vall-llossera

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer - Business Wire

Radiopharma startup Artbio raises $90M in sign of field’s momentum - BioPharma Dive

BIO announces new CEO—Chutes & Ladders


                Leading with Lead #5
              

Apply for this job

 Women played a leading role in the pandemic-fueled boom in ... 

The group I'm in at ARTBIO is growing! We are looking for a biochemist/biophysicist with some plate based assay experience (SPR or ITC experience are a plus)! Reach out if you're interested or know someone that might be a good fit! 

 https://lnkd.in/ePUZqZVk 

ClinicalSenior Medical Director, Clinical DevelopmentCambridge, MA

Week In Review: AlphaGen And ArtBio Form China-U.S. Radioligand Partnership - Seeking Alpha

Investors pour $90M onto ARTBIO's palette 6 months after ...

 ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials 

ARTBIO Announces Appointment of Margaret Yu, M.D., as Chief Medical OfficerARTBIO | January 9, 2025

Novartis, Lilly drive investor interest in radiopharmaceuticals

www.artbio.com

SpectronRx, ARTBIO Partner on Alpha Radioligand Therapy - Contract Pharma

ARTBIO Home Page

ARTBIO is looking for a Senior Medical Director to join their team. The company is focused on alpha-RLT for cancer care, with their lead program currently in First-in-Human studies. This role is an exciting leadership opportunity in clinical development within the field of oncology!

If you are interested, feel free to reach out or apply directly. #MedicalDirector #ClinicalDevelopment #Oncology #HealthcareCareers #RadioligandTherapy

Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia - Endpoints News


              Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 2025
            

 FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle ... 

 Artbio raises $23M to advance lead-based radioligand therapies for prostate cancer 

 Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates 

 Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia 

 The Week's 10 Biggest Funding Rounds: X-Energy And ... 

Research & DevelopmentResearch Associate II/Senior Research Associate, BiologyCambridge, MA

Check out this job at ARTBIO: CDMO Tech Transfer Lead

Investors pour $90M onto ARTBIO's palette less than 6 months after launching - Fierce Biotech

 ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology 

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid TumorsARTBIO, 3B Pharmaceuticals | November 14, 2024

Research & DevelopmentPrincipal Scientist/Associate Director, Peptide ChemistryCambridge, MA


                Part 4: Leading with Lead
              

 ARTBIO’s Exclusive Strategic Collaboration with AlphaGen Therapeutics 

 Artbio raises $90M as radiopharma field finds its footing 

ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology - PR Newswire

 ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New ... 

 ARTBIO Raises $90M in Series A Financing 

Finance & AccountingClinical Trial Finance AssociateLondon

Principal Investigator Dr. Kjetil Berner from Oslo University Hospital will be presenting early clinical data on ARTBIO’s lead program, AB001, a PSMA-targeted 212Pb #Alpha #Radioligand #Therapy for metastatic castration resistant prostate cancer (#mCRPC), at the 2024 European Multidisciplinary Congress on Urological Cancers (#EMUC24).
 
The poster presentation highlights data from the Phase 0 imaging study of AB001. Gamma camera imaging following a 212Pb AB001 microdose showed tumor targeting and promising biodistribution. This early clinical research could lead to more treatment options for patients with prostate cancer in the future. View the poster here: https://lnkd.in/et7_p356
 
Be sure to stop by to learn how we are redefining cancer care by developing a new class of #Alpha #Radioligand #Therapies (#ARTs) based on the ideal isotope #Pb212.
 
#RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine #Oncology #ProstateCancer


                Radioligand Therapy: A New Cancer Treatment Paradigm?
              

The ARTBIO team is excited to be attending several upcoming events in the coming weeks, including the William Blair Conference, the ICPO Foundation-International Centers for Precision Oncology Theranostics Summit, and the 2024 Jefferies London Healthcare Conference!

ARTBIO Chief Scientific Officer Nick Pullen will be speaking at the ICPO Summit with a first disclosure of pre-clinical data underwriting the superiority of alpha emission in a bone metastasis Prostate Cancer model, as well as clinical data from a Ph0 evaluation of AB001.

ARTBIO Chief Executive Officer Emanuele Ostuni will be joining Andy Hsieh for a fireside chat as part of the William Blair’s Innovator Series: Radiopharmaceuticals, discussing ARTBIO’s vision for Pb212-based alpha radioligand therapies and the progress the company has made since its inception.

We look forward to insightful discussions and sharing the latest updates about our approach to #Alpha #Radioligand #Therapies (#ART). Find out more about our unique approach at https://artbio.com/

#WilliamBlair #JefferiesHealthcare #RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine

ARTBIO will attend the 4th annual ICPO Foundation-International Centers for Precision Oncology Forum in Garching, Germany, and our VP Clinical Development Vicki Jardine is presenting Pb212 clinical opportunities for targeted #alpha #radioligand #therapies.
 
Be sure to check out her session on May 16th at 15:30 CET.
 
#nuclearmedicine #biotech #radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare

The ARTBIO team is excited to attend both the Hanson Wade Group’s 6th Annual Targeted Radiopharmaceuticals Summit Europe and the 36th Annual Piper Sandler Healthcare Conference from December 3-5!

At the Targeted Radiopharmaceuticals Summit Europe in Amsterdam, we’ll connect with industry leaders to exchange insights, explore innovative solutions, and contribute to discussions advancing radiopharmaceutical therapies. Our colleagues Vicki Jardine and Daniel Rossetto will share ARTBIO’s vision for Pb212-based #Alpha #Radioligand #Therapies (#ART).

Emanuele Ostuni is looking forward to in-depth discussions on emerging trends, connecting with experts, and gaining fresh strategies at the Piper Sandler Healthcare Conference. We hope to see you there! 

Learn more about our innovative methods and recent partnerships at https://artbio.com/

#RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine


                Part 3: Leading with Lead
              

 Radionuclide generator 

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies - PR Newswire


                Part 2: Leading with Lead
              

Excited to be heading to Bergen soon for this year's LSX Nordic Congress (20-21 May) to (re)connect and exchange with peers, academia and investors. Especially looking forward to our panel discussion on the evolving world of #radiopharmaceuticals.

Oystein Soug Jutta Heix Lars Mørland Knudsen Frans Suurs ARTBIO Oslo Cancer Cluster Oncoinvent ASA p53 Bayer

#nuclearmedicine #radioligandtherapy

 RLS expands by offering radiopharmaceutical contract ... 

Norwegian biotech startup nabs $23M seed to develop radiopharmaceuticals for prostate cancer - ArcticStartup - ArcticStartup

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of CancerARTBIO, FogPharma | May 14, 2024

FogPharma, ARTBIO Partner To Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma

 Nucleus RadioPharma unveils manufacturing pact with ARTBIO 

ARTBIO

Business:

Drug notes:

About: